- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Ascentage Pharma received FDA clearance for lisaftoclax treatment, with investigators from Peking University and MD Anderson leading the trial.
1 report, 1 independent
Updated Aug 20
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ascentage Pharma received FDA clearance for lisaftoclax treatment, with investigators from Peking University and MD Anderson leading the trial.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
- FDA
-
Peking University
university in Beijing, China
Nothing else this week.
-
Alena Kohušová
Czech singer and saxophonist
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- Exec EdgeAscentage Pharma’s Lisaftoclax Gets FDA/EMA Clearance By Daniella Parra Ascentage Pharma (NASDAQ: AAPG) said it received FDA and EMA clearance for GLORA-4, a global registrational Phase III trial of